Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer
Authors
Keywords
Breast cancer, HDAC, Tucidinostat, Selinexor, p53
Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 545, Issue -, Pages 111558
Publisher
Elsevier BV
Online
2022-01-14
DOI
10.1016/j.mce.2022.111558
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of p53 in transcriptional repression of SVCT2
- (2021) Eun Ho Kim et al. MOLECULAR BIOLOGY REPORTS
- Chidamide Combined With Doxorubicin Induced p53-Driven Cell Cycle Arrest and Cell Apoptosis Reverse Multidrug Resistance of Breast Cancer
- (2021) Lixia Cao et al. Frontiers in Oncology
- Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer
- (2021) Yanchun Meng et al. Annals of Palliative Medicine
- Exportin 1 inhibition as antiviral therapy
- (2020) Md. Hafiz Uddin et al. DRUG DISCOVERY TODAY
- Breast cancer: Biology, biomarkers, and treatments
- (2020) Khadijeh Barzaman et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
- (2020) Terence C. S. Ho et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers
- (2020) Eylem Kulkoyluoglu Cotul et al. Cancers
- p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
- (2019) Maria Mrakovcic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer
- (2019) Michael Shafique et al. ONCOLOGIST
- Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Zefei Jiang et al. LANCET ONCOLOGY
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Histone Acetylation Modifications of Breast Cancer and their Therapeutic Implications
- (2018) Pingping Guo et al. PATHOLOGY & ONCOLOGY RESEARCH
- Nuclear Export Inhibition for Pancreatic Cancer Therapy
- (2018) Irfana Muqbil et al. Cancers
- Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
- (2017) Yuankai Shi et al. Journal of Hematology & Oncology
- CRM1 Inhibitors for Antiviral Therapy
- (2017) Cynthia Mathew et al. Frontiers in Microbiology
- Targeting Cancer at the Nuclear Pore
- (2016) Asfar S. Azmi et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling
- (2015) F. Conforti et al. CLINICAL CANCER RESEARCH
- Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
- (2014) Kaushal Parikh et al. Journal of Hematology & Oncology
- Promising SINEs for Embargoing Nuclear-Cytoplasmic Export as an Anticancer Strategy
- (2014) D. S. P. Tan et al. Cancer Discovery
- Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine
- (2013) Yushi Yao et al. PLoS One
- Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
- (2012) Li Shen et al. OncoImmunology
- The impact of acetylation and deacetylation on the p53 pathway
- (2011) Christopher L. Brooks et al. Protein & Cell
- Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 Integrase
- (2008) G. S. Jones et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now